U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06416241) titled 'Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion' on May 8.
Brief Summary: Central retinal vein occlusion (CRVO) is a common retinal vascular disorder, occurring when there is a blockage to the main blood vessel that transports blood away from the retina. CRVO may cause visual impairment, especially due to macular edema (swelling of the macula due to fluid accumulation) and macular non-perfusion.
Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials.
The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world...